Suppr超能文献

罗克洛激酶抑制剂作为帕金森病治疗选择的分子动力学研究。

Molecular dynamic investigation for Roco4 kinase inhibitor as treatment options for parkinsonism.

机构信息

Department of Life Sciences, University of Trieste, 34132, Trieste, Italy.

Department of Food Technology, Faculty of Life and Allied Health Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, 560054, Karnataka, India.

出版信息

J Mol Model. 2024 Apr 16;30(5):133. doi: 10.1007/s00894-024-05925-0.

Abstract

CONTEXT

Parkinson's disease is a neurodegenerative condition characterized by the degeneration of dopaminergic neurons, resulting in motor disabilities such as rigidity, bradykinesia, postural instability, and resting tremors. While the exact cause of Parkinson's remains uncertain, both familial and sporadic forms are often associated with the G2019S mutation found in the kinase domain of LRRK2. Roco4 is an analogue of LRRK2 protein in Dictyostelium discoideum which is an established model organism to investigate LRRK2 inhibitors. In this study, the potential treatment of Parkinson's was explored by inhibiting the activity of the mutated LRRK2 protein using Roco4 as the base protein structure. Mongolicain-A and Bacoside-A exhibited significant selectivity towards the G2019S mutation, displaying a binding affinity of - 12.3 Kcal/mol and - 11.4 Kcal/mol respectively. Mongolicain-A demonstrated increased specificity towards Roco4, while Bacoside-A demonstrated significant binding affinity to all 34 kinases proteins alike. The Molecular Dynamics Studies (MDS) results strongly suggests that Mongolicain-A is a significant inhibitor of Roco4 kinase. ADMET and drugability analysis also suggests that among the two best ligands, Mongolicain-A demonstrates significant physicochemical properties to be suitable for best drug like molecule. Based on the in-silico molecular docking, molecular dynamic simulation, ADMET and drugability analyses, it is strongly suggested that, Mongolicain-A could be a potential candidate for treatment and management of Parkinson's disease via inhibition of LRRK2 protein. Further in-vitro and in-vivo investigations are in demand to validate these findings.

METHODS

To identify potential inhibitors, 3069 phytochemicals were screened using molecular docking via AutoDock Vina. Molecular Dynamics Simulation was carried out using GROMACS 2022.2 for a duration of 100ns per complex to study the stability and inhibition potential of the protein ligand complexes. ADMET analysis was carriedout using Molinspiration and preADMET web tool.

摘要

背景

帕金森病是一种神经退行性疾病,其特征是多巴胺能神经元退化,导致运动障碍,如僵硬、运动迟缓、姿势不稳和静止性震颤。虽然帕金森的确切病因尚不清楚,但家族性和散发性帕金森病通常与 LRRK2 激酶结构域中发现的 G2019S 突变有关。Roco4 是盘基网柄菌(一种已建立的用于研究 LRRK2 抑制剂的模式生物)中 LRRK2 蛋白的类似物。在这项研究中,通过使用 Roco4 作为基础蛋白结构来抑制突变的 LRRK2 蛋白的活性,探索了帕金森病的潜在治疗方法。蒙古春碱-A 和 Bacoside-A 对 G2019S 突变表现出显著的选择性,结合亲和力分别为-12.3 Kcal/mol 和-11.4 Kcal/mol。蒙古春碱-A 对 Roco4 表现出更高的特异性,而 Bacoside-A 对所有 34 种激酶蛋白都表现出显著的结合亲和力。分子动力学研究(MDS)结果强烈表明,蒙古春碱-A 是 Roco4 激酶的重要抑制剂。ADMET 和可药性分析还表明,在这两种最佳配体中,蒙古春碱-A 具有显著的物理化学性质,适合作为最佳类药分子。基于计算机分子对接、分子动力学模拟、ADMET 和可药性分析,强烈表明,蒙古春碱-A 可能通过抑制 LRRK2 蛋白成为治疗和管理帕金森病的潜在候选药物。需要进一步的体外和体内研究来验证这些发现。

方法

为了鉴定潜在的抑制剂,使用 AutoDock Vina 通过分子对接筛选了 3069 种植物化学物质。使用 GROMACS 2022.2 进行分子动力学模拟,每个复合物持续 100ns,以研究蛋白质配体复合物的稳定性和抑制潜力。ADMET 分析使用 Molinspiration 和 preADMET 网络工具进行。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验